ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2
ASX health stock Race Oncology has completed the dose escalation stage of its Phase 1b/2 Zantrene study into ALM ( (acute myeloid leukemia).
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
